The document summarizes results from a phase 3 clinical trial of the drug odanacatib for treating osteoporosis in postmenopausal women. Key findings include:
- Odanacatib significantly reduced the risk of morphometric vertebral fractures by 54%, hip fractures by 47%, and nonvertebral fractures by 23% compared to placebo.
- Bone mineral density increased substantially with odanacatib therapy over 5 years.
- Safety analyses found low rates of adverse events with odanacatib, though some rare skin conditions were more common compared to placebo and require further investigation.
Vertebro/kyfoplastiek: bewezen effectief of (nog) niet bewezen effectief, presentatie van Mw. Dr. C.A.H. Klazen op 23/24 november 2012 voor de Stichting IWO.
This study examined the relationship between trabecular bone score (TBS) and prevalent and incident vertebral fractures in elderly women. TBS was significantly associated with an increased risk of both prevalent and incident vertebral fractures, independent of bone mineral density measured by dual-energy X-ray absorptiometry. Combining TBS and BMD measurements slightly improved the prediction of fracture risk compared to BMD alone. The study suggests TBS provides additional information on bone quality and fracture risk beyond BMD.
The document summarizes results from a phase 3 clinical trial of the drug odanacatib for treating osteoporosis in postmenopausal women. Key findings include:
- Odanacatib significantly reduced the risk of morphometric vertebral fractures by 54%, hip fractures by 47%, and nonvertebral fractures by 23% compared to placebo.
- Bone mineral density increased substantially with odanacatib therapy over 5 years.
- Safety analyses found low rates of adverse events with odanacatib, though some rare skin conditions were more common compared to placebo and require further investigation.
Vertebro/kyfoplastiek: bewezen effectief of (nog) niet bewezen effectief, presentatie van Mw. Dr. C.A.H. Klazen op 23/24 november 2012 voor de Stichting IWO.
This study examined the relationship between trabecular bone score (TBS) and prevalent and incident vertebral fractures in elderly women. TBS was significantly associated with an increased risk of both prevalent and incident vertebral fractures, independent of bone mineral density measured by dual-energy X-ray absorptiometry. Combining TBS and BMD measurements slightly improved the prediction of fracture risk compared to BMD alone. The study suggests TBS provides additional information on bone quality and fracture risk beyond BMD.
Vertebral Fracture Identification presented by Dr Andrew Pearson, Consultant Radiologist, Borders Hospital, Melrose at the fracture liaison service champions' summit 2016. #flschampions
Vertebral Fracture Management Professor presented by Opinder Sahota, Orthogeriatric Medicine & Consultant Physician QMC, Nottingham University Hospitals NHS Trust.
Presented at the FLS Champions' Summit, February 2016.
This summary provides the key points from the document in 3 sentences:
Screening older women for vertebral fractures using a systematic approach can improve case finding. The COSHIBA study found that using a simple screening tool to identify women at high risk of vertebral fractures led to more prescriptions of osteoporosis medication and fewer new fractures over 12 months compared to standard care. Vertebral fractures are clinically important to identify as they significantly increase future fracture risk independent of bone mineral density measurements.
This document provides an overview of balloon kyphoplasty as an orthopaedic treatment for vertebral compression fractures. It describes how balloon kyphoplasty can stabilize fractures and correct spinal deformity by using an inflatable balloon to restore height to a fractured vertebra before injecting bone cement. Clinical studies discussed show that balloon kyphoplasty provides significant pain reduction, mobility improvements, and a low complication rate compared to alternative treatments like vertebroplasty.
Operative treatment of osteoporotic spinal fracturesAlexander Bardis
Osteoporosis can lead to spinal fractures that are traditionally treated with bed rest, braces, and pain medications. However, this risks further bone loss and weakness. The document discusses operative treatments for osteoporotic spinal fractures including spinal fixation and minimally invasive techniques like vertebroplasty and kyphoplasty. It outlines challenges posed by osteoporosis like early and late hardware failure. Methods to improve screw fixation in weak bone are described, such as cement augmentation, screw design modifications, and technique adjustments. Vertebroplasty and kyphoplasty provide pain relief but kyphoplasty can restore lost height while vertebroplasty risks cement leakage. Operative fixation and minimally invasive treatments can successfully
Vertebroplasty is an effective, minimally invasive spine procedure where acrylic bone cement is injected into a painful pathologically compressed vertebral body.
Determinants of dyspnea and its predictive value for adverse outcomes in the ...Chiel Hex
Determinants of dyspnea and its predictive value for adverse outcomes in the cohort of very old adults.
Determinanten van dyspnea en de predicatieve waarde ervan bij ouderen.
Vertebral Fracture Identification presented by Dr Andrew Pearson, Consultant Radiologist, Borders Hospital, Melrose at the fracture liaison service champions' summit 2016. #flschampions
Vertebral Fracture Management Professor presented by Opinder Sahota, Orthogeriatric Medicine & Consultant Physician QMC, Nottingham University Hospitals NHS Trust.
Presented at the FLS Champions' Summit, February 2016.
This summary provides the key points from the document in 3 sentences:
Screening older women for vertebral fractures using a systematic approach can improve case finding. The COSHIBA study found that using a simple screening tool to identify women at high risk of vertebral fractures led to more prescriptions of osteoporosis medication and fewer new fractures over 12 months compared to standard care. Vertebral fractures are clinically important to identify as they significantly increase future fracture risk independent of bone mineral density measurements.
This document provides an overview of balloon kyphoplasty as an orthopaedic treatment for vertebral compression fractures. It describes how balloon kyphoplasty can stabilize fractures and correct spinal deformity by using an inflatable balloon to restore height to a fractured vertebra before injecting bone cement. Clinical studies discussed show that balloon kyphoplasty provides significant pain reduction, mobility improvements, and a low complication rate compared to alternative treatments like vertebroplasty.
Operative treatment of osteoporotic spinal fracturesAlexander Bardis
Osteoporosis can lead to spinal fractures that are traditionally treated with bed rest, braces, and pain medications. However, this risks further bone loss and weakness. The document discusses operative treatments for osteoporotic spinal fractures including spinal fixation and minimally invasive techniques like vertebroplasty and kyphoplasty. It outlines challenges posed by osteoporosis like early and late hardware failure. Methods to improve screw fixation in weak bone are described, such as cement augmentation, screw design modifications, and technique adjustments. Vertebroplasty and kyphoplasty provide pain relief but kyphoplasty can restore lost height while vertebroplasty risks cement leakage. Operative fixation and minimally invasive treatments can successfully
Vertebroplasty is an effective, minimally invasive spine procedure where acrylic bone cement is injected into a painful pathologically compressed vertebral body.
Determinants of dyspnea and its predictive value for adverse outcomes in the ...Chiel Hex
Determinants of dyspnea and its predictive value for adverse outcomes in the cohort of very old adults.
Determinanten van dyspnea en de predicatieve waarde ervan bij ouderen.
IWO Meeting 1 November 2023 - Stopping with Denosumab and Romosozumab, basic mechanisms and clinical aspects door Prof. dr. S. Ferrari, Geneva, Switzerland. (Engelstalige lezing)
1) DXA scanning is a reliable and low-radiation method to measure bone mineral density (BMD) at the lumbar spine, hip, and wrist to diagnose osteoporosis.
2) DXA can also detect vertebral fractures (VFA) and measure whole body composition, abdominal fat, and aortic calcification.
3) Interpretation of DXA results requires attention to potential variability between devices, accurate placement of regions of interest, and use of appropriate reference data since BMD can be under or overestimated in certain patients.
This document summarizes osteonecrosis of the jaw (ONJ) associated with antiresorptive agents. It defines ONJ and stages its severity. It discusses the pathogenesis of ONJ and risk factors like underlying disease, treatment duration, and dental procedures. Cancer patients on intravenous bisphosphonates have the highest ONJ risk of 1-8% due to higher drug doses and worse oral/general health. Management involves conservative measures like mouthwashes for early stages and surgery with antibiotics for later stages. Discontinuing antiresorptives may help healing but risks fractures. Teriparatide may help healing in some cases but its use in cancer is uncertain. More research is needed on preventing and treating established ON
This systematic review analyzed 895 cases of tumor-induced osteomalacia (TIO) from case reports. TIO is caused by tumors that produce excess fibroblast growth factor 23 (FGF23), which causes hypophosphatemia and osteomalacia. The review found that TIO mostly affects adults aged 40-60 years old, with long diagnostic delays of several years on average. The tumors were located variably but most commonly in the lower limbs or head and neck region. Higher FGF23 levels correlated with larger tumor size. Patients experienced significant bone fragility and fracture rates as high as 60% due to long-term hypophosphatemia. Early tumor detection and removal are important to improve outcomes for
This document discusses real-world evidence on denosumab for osteoporosis treatment and fracture prevention. It summarizes several studies, including one that found denosumab reduced fracture risk by 38% compared to placebo in over 25,000 postmenopausal women. Another study showed good long-term persistence with denosumab therapy in over 800 patients. Additional studies observed that zoledronic acid can prevent bone loss following denosumab discontinuation, and bisphosphonate treatment after denosumab provides protection against new vertebral fractures.
IWO Meeting 16 November 2022 - ASBMR young talent: Silvia Storoni (Amsterdam): Prevalence and Hospital Admissions in Patients With Osteogenesis Imperfecta in The Netherlands: A Nationwide Registry Study
The document appears to be a presentation on highlights from the ASBMR 2021 conference in San Diego. It discusses several topics that were covered at the conference, including fracture risk assessment, the effects of various osteoporosis treatments on bone mineral density, safety issues like osteonecrosis of the jaw and atypical femoral fractures, the role of vitamin D, and applications of artificial intelligence. The entire document is copyrighted by Prof. Dr. Joop van den Bergh.
This document discusses guidelines for medication to prevent fractures in patients using glucocorticoids. It notes that glucocorticoids significantly increase the risk of vertebral and non-vertebral fractures. While effective anti-osteoporosis drugs are available, many glucocorticoid-treated patients remain untreated. The document reviews new guidelines that simplify treatment criteria to improve implementation and outlines recommendations for when to start bone-sparing medications based on patient factors and glucocorticoid dose and duration. The goal is to optimize fracture prevention in glucocorticoid-treated patients.
This document discusses what actions should be taken when a vertebral fracture is discovered incidentally. It notes that vertebral fractures are very common fractures, especially in older individuals, and are often asymptomatic. Having a vertebral fracture significantly increases one's risk for future fractures both in the short and long term. If a vertebral fracture is found incidentally, such as on a CT scan, further investigation is warranted including assessing bone mineral density and checking for underlying bone diseases. Treatment options should also be considered, especially if the individual has low bone density in addition to the vertebral fracture, as this combination confers the highest risk. New automated detection algorithms aim to help identify vertebral fractures on scans to ensure appropriate follow up for individuals.
This document summarizes a cost-effectiveness model of Fracture Liaison Services (FLS) care in the Netherlands. The model found that FLS care would be highly cost-effective, with a cost of €9,076 per quality-adjusted life year gained. Total 5-year costs with FLS would be only 1.7% higher than current costs but would prevent fractures and improve health outcomes. The model can help decision-makers prioritize secondary fracture prevention and allow local payers and FLS to predict costs and benefits of implementation.
This document discusses recommendations from the European Calcified Tissue Society (ECTS) regarding treatment after stopping denosumab therapy. It summarizes findings from ECTS papers in 2017 and 2021 on risks of rebound vertebral fractures when discontinuing denosumab. The ECTS recommends pretreatment or post-treatment with bisphosphonates to prevent bone mineral density loss and fractures after stopping denosumab, especially for those on long-term denosumab therapy of over 2.5 years. New Dutch guidelines advise treating with denosumab for 3 years, then reevaluating fracture risk before extending treatment another 3 years up to a maximum of 10 years, and ensuring adequate bisphosphonate treatment after stopping to prevent
IWO bijeenkomst - 14 april - Prof. Dr. J.P. van den Bergh
Seminar 08-10-2014 H. van der Jagt Willems- Time to benefit
1. HANNA VAN DER JAGT , WILLEMS
UITNODIGING
voor(het(bijwonen(van(de(openbare(
verdediging(van(mijn(proefschrift
VERTEBRAL FRACTIONS
IN GERIATRIC PATIENTS:
PREVALENCE AND
CLINICAL RELEVANCE
door(Hanna(van(der(JagtCWillems
Maandag(3(november(2014,(
om(15.45(uur(precies(in(het((
Auditorium(van(het(hoofdgebouw(
van(de(Vrije(Universiteit(
De(Boelelaan(1105(
1081(HV((Amsterdam(
(
uitgenodigd(voor(de(receptie(ter(
plaatse.(
Hanna(van(der(JagtCWillems(
Lorentzlaan(23(
2105(TP(Heemstede(
Paranimfen:(
Maartje(de(Groot(en((
Manon(Kerkhof(
hanna.promoveert@gmail.com
PREVALENCE AND CLINICAL RELEVANCE
H
.van
derJagt-W
illem
s
2. Is
er
‘'me
to
benefit’
bij
hoogbejaarden
met
osteoporose?
Hanna
van
der
Jagt-‐Willems
IWO,
8
oktober
2014
H
.van
derJagt-W
illem
s
3. Fracturen
nemen
toe
naarmate
men
ouder
wordt,
exponen'eel
boven
de
80
jaar
Sambrook
and
Cooper,
Lancet
2006
50
60
70
80
50
60
70
80
H
.van
derJagt-W
illem
s
4. SchrijP
u
medica'e
voor
aan
deze
vrouw?
88
jaar,
recente
heupfractuur,
wervelfractuur
T8,
Voorgeschiedenis:
HarValen
na
MI
COPD
GOLD
2
Medica'e
o.a.:
CAD
500/880
H
.van
derJagt-W
illem
s
6. Doel
van
het
onderzoek
1. Wordt
'me
to
benefit
berekend
in
de
literatuur?
Hoe?
2. Wat
is
de
'me
to
benefit
van
osteoporose
medica'e?
3. Berekening
met
SPC
methode
op
de
database
van
de
FIT
(alendroninezuur)
H
.van
derJagt-W
illem
s
7. Wordt
TTB
berekend?
Hoe?
• 2
hits
op
term
TTB
• review
osteoporose
medica'e
(325):
7
met
'me
to
event
analyse:
– 5
survival
analyses:
Kaplan
Meier
/
Cox
Regression
model
– 1
risico-‐reduc'e
analyse
– 1
Hazard
Ra'o
model
over
aantal
maanden
H
.van
derJagt-W
illem
s
8. Wat
is
de
TTB
van
bisfosfonaten?
• Literatuur-‐review
osteoporose
medica'e
(325)
• 7
ar'kelen:
– 5
survival
analyses:
Kaplan
Meier
/
Cox
Regression
model
– 1
risico-‐reduc'e
analyse
– 1
Hazard
Ra'o
model
over
aantal
maanden
H
.van
derJagt-W
illem
s
10. Effect
FIT
trial
1Black
et
al.
JCEM
2000
H
.van
derJagt-W
illem
s
11. • Kunnen
we
de
'me
to
benefit
berekenen?
• SPC
(Sta's'cal
Proces
Controle)
als
methode
H
.van
derJagt-W
illem
s
12. Sta's'sche
Proces
Controle
(SPC)
• Evalueert
repeterend
proces
• Meet
verwachte
uitkomst:
– Gemiddelden
– Varia'e
(SD)
• ‘Out
of
control’:
– ±3
Sigma
– Tolerance
limits
H
.van
derJagt-W
illem
s
13. TTB
en
SPC
• Het
eerste
moment
waarop
het
proces
out
of
control
gaat,
in
het
voordeel
van
het
middel
(alendronaat)
• TTB
(fractuur)
in
maanden
H
.van
derJagt-W
illem
s
14. Fracture
Interven'on
Trial
• RCT
• postmenopausale
vrouwen
met
osteoporose
(T<
-‐2.5
of
wervelfractuur)
• alendronaat
versus
placebo
• elke
klinische
fractuur
• Ruwe
data:
exacte
moment
van
optreden
van
fractuur
Black
JCEM,
2000
H
.van
derJagt-W
illem
s
15. Pa'ënt
karakteris'eken
FIT
trial
Alendronaat (n=1841) Placebo (n=1817)
Leeftijd, gem (SD) 69 (6.0) 69 (5.9)
Klinische fractuur na 45ste jaar, n 935 (51%) 907 (50%)
T-score heup (SD) -2.74 (0.55) -2.76 (0.55)
Klinische fracturen tijdens follow up, n 248 (14%) 341 (19%)
Overleden tijdens follow up, n 40 (2%) 36 (2%)
1Black
et
al.
JCEM
2000
H
.van
derJagt-W
illem
s
16. N
=
3,658,
T
score
<-‐2.5
of
prevalente
wervelfractuur.
ARR
bij
11
mnd
=1.1%
H
.van
derJagt-W
illem
s
17. >70
jaar
en
OP:
N=
1,870.
ARR
op
8
maanden=
1,4%
H
.van
derJagt-W
illem
s
18. <70
jaar
met
OP
n=
1,788,
ARR
op
19
mnd
=
0.7%
H
.van
derJagt-W
illem
s
19. Conclusies
• Time
to
benefit
is
korter
bij
ouderen
• Moment
van
significan'e
kleine
absolute
risico
reduc'es
(~
1%)
• Alleen
klinische
fracturen
geincludeerd,
geen
s'lle
wervelfracturen.
Sneller
effect?
H
.van
derJagt-W
illem
s
20. Discussie
• Time
to
benefit
is
een
belangrijke
maat
om
te
kunnen
afwegen
of
preven'eve
medica'e
nog
zinvol
is
bij
een
beperkte
levensverwach'ng
• Time
to
benefit
wordt
doorgaans
bij
RCT’s
niet
berekend,
dat
is
een
omissie
• Time
tot
benefit
is
te
berekenen
met
SPC
methode,
welke
gemakkelijk
te
interpreteren
is.
H
.van
derJagt-W
illem
s
21. Auteurs
• Esther
van
de
Glind
• Saied
Eslami
Hassanabadi
• Ameen
Abu-‐Hanna
• Willem
Lems
• Barbara
van
Munster
• Sophia
de
Rooij
• Dennis
Black
(USA)
H
.van
derJagt-W
illem
s